Leadership And ExpertiseJade Biosciences is led by a world-class team that previously sold its IgAN portfolio to Novartis for a substantial amount, indicating strong leadership and expertise.
Market PotentialJADE-001 is anticipated to capture a significant share of the potential $10B+ IgAN market, with projected global sales reaching billions.
Product PotencyJADE-001 is an anti-APRIL mAb with significantly greater potency than its competitors and a potential longer dosing interval, offering an optimal benefit-risk profile for chronic therapy.